

1 Molecular characterization of methicillin-resistant and susceptible *Staphylococcus*  
2 *aureus* recovered from hospital personnel

3 **Running title:** Molecular characterization of *S. aureus*

4 Zhen Xu <sup>1,2,3</sup>, Xiaodong Li<sup>1,2,3</sup>, Dan Tian<sup>1,2,3</sup>, Zhuoyu Sun<sup>1,2,3</sup>, Liqiong Guo <sup>1,2,3</sup>, Cuixia  
5 Dong<sup>1,2,3</sup>, Naijun Tang<sup>1,2,3</sup>, Hermine V Mkrтчyan<sup>4\*</sup>

6 1 Department of Toxicology and Sanitary Chemistry, School of Public Health,  
7 Tianjin Medical University, Qixiang Road No. 22, Tianjin, China

8 2 Tianjin Key Laboratory of Environment, Nutrition and Public Health, Tianjin  
9 Medical University, Qixiang Road No 22. Tianjin, China

10 3 Center for International Collaborative Research on Environment, Nutrition and  
11 Public Health, School of Public Health, Tianjin Medical University, Qixiang Road  
12 No. 22, Tianjin, China

13 4 School of Biomedical Sciences, University of West London, St Mary's Rd, London,  
14 UK

15 Correspondence:

16 \*Hermine V Mkrтчyan:

17 School of Biomedical Sciences, University of West London, St Mary's Rd, London, UK,

18 W5 5RF

19 E-mail: [hermine.mkrтчyan@uwl.ac.uk](mailto:hermine.mkrтчyan@uwl.ac.uk)

20

21

22 **Abstract**

23 Introduction

24 Methicillin resistant *Staphylococcus aureus* (MRSA) is one of the major causes of  
25 hospital acquired infections. Over the past two decades MRSA has become ‘epidemic’  
26 in many hospitals worldwide. However, little is known about the genetic background  
27 of *S. aureus* recovered from hospital personnel in China.

28 Aim

29 The aim of this study was to determine the genetic diversity of MRSA and methicillin  
30 susceptible *S. aureus* (MSSA) recovered from hospital personnel in Tianjin, North  
31 China.

32 Methodology

33 Three hundred and sixty-eight hand or nasal swabs were collected from 276 hospital  
34 personnel in four tertiary hospitals in Tianjin, North China between November 2017  
35 and March 2019. In total, 535 gram-positive bacteria were isolated, of which 59 were  
36 identified as *S. aureus*. Staphylococcal cassette chromosome *mec* (SCC*mec*) typing,  
37 multi-locus sequence typing (MLST) and *spa* typing were performed to determine  
38 molecular characteristics of *S. aureus*.

39 Results

40 Thirty-one out of 276 (11%) hospital personnel were *S. aureus* carriers, whereas 11/276  
41 (4%) carried MRSA. Fifty out of 59 (85%) of *S. aureus* isolates were resistant or  
42 intermediate resistant to erythromycin. The dominant genotypes of MRSA recovered  
43 from hospital personnel were ST398-t034-SCC*mec*IV/V, and ST630-t084/t2196,

44 whereas major genotypes of MSSA included ST15-t078/t084/t346/t796/t8862/  
45 t8945/t11653 and ST398-t189/t034/ t078/t084/t14014.

#### 46 Conclusion

47 Although, the predominant genotypes of MRSA recovered from hospital personnel in  
48 this study were different from those main genotypes that have previously been reported  
49 to cause infections in Tianjin and in other geographic areas of China, the MRSA ST398-  
50 t034 genotype has previously been reported to be associated with livestock globally.  
51 The dominant MSSA genotypes recovered from hospital personnel were consistent with  
52 those previously reported MSSA genotypes recovered from the clinic. The diversity of  
53 *S. aureus* genotypes warrantee further surveillance and genomic studies to better  
54 understand the relatedness of these bacteria with those recovered from patients and  
55 community.

56 **Key words:** *Staphylococcus aureus*, hospital personnel, *spa* typing, MLST

57

58

59 **Introduction**

60 Associated with healthcare, community and livestock methicillin resistant *S. aureus*  
61 (MRSA) is a major public health concern worldwide. 29%-35% of clinical isolates  
62 recovered in healthcare settings in the US and Europe are MRSA responsible for mild  
63 to life threatening infections [1,2]. Additionally, this bacterium has developed  
64 resistance to multiple antibiotics subsequently limiting treatment options.

65 *S. aureus* can be transmitted via person to person or person to inanimate objects contact.

66 Due to their occupation, hospital personnel have been implicated in the transmission of  
67 MRSA to vulnerable patients and acted as a vector for such transmission between the  
68 patients and hospital environments [3]. The Chinese National Surveillance study  
69 (CNSS) carried out in 2013 found that ST239-t030/t037-SCCmec III and ST5-  
70 t002/t570-SCCmec II were predominant MRSA genotypes responsible for clinical  
71 infections in China, whereas ST7-t091/t796, ST188-t189 and ST398-t571/t034 were  
72 the major genotypes of methicillin-susceptible *S. aureus* (MSSA) causing clinical  
73 infections in China [4]. However, little is known about the genotypes circulating among  
74 hospital personnel in China, hence it has been challenging to find common interfaces  
75 between major MRSA/MSSA clones recovered from patients and hospital personnel.

76 In this study we report the antibiotic susceptibility, molecular characterization and  
77 genetic diversity of MRSA and MSSA recovered from hospital personnel in Tianjin,  
78 North China.

79 **Methods**

80 **Specimen collection**

81 A total of 368 samples were collected from four hospital (Nankai hospital, Tianjin  
82 Medical University General Hospital, Tianjin Central Hospital of Gynecology  
83 Obstetrics and Tianjin Baodi hospital) personnel (n=276) between November 2017 and  
84 March 2019.

85 Cotton swabs (Yangsheng Biotech, China) were used to collect samples from anterior  
86 nares of hospital personnel. The cotton swab was gently inserted into one of the nostrils  
87 up to 1 cm and was rotated 3 times to sample the inner surfaces [5]. Hand samples were  
88 collected using sterile PBS buffer – soaked cotton swabs. Swab- based samples were  
89 taken from palmar side of both hands [6]. All samples were transferred back to the lab  
90 within 1 h of sampling. The research protocol and informed consent was approved by  
91 the Ethics committee of Tianjin Science and Technology Commission (approval No  
92 TMUaMEC2017017). All research was performed in accordance with the relevant  
93 guidelines and regulations. Informed consent was obtained from all participants.

94 All specimens were inoculated onto mannitol salt agar (MSA, Oxoid, Basingstoke, UK),  
95 and incubated aerobically at 37°C for 24 to 72 hours. Colonies with typical *S. aureus*  
96 characteristics were purified using nutrient agar (NA, Oxoid, Basingstoke, UK).

#### 97 **Identification of *S. aureus* isolates**

98 For identification at species level, all *S. aureus* isolates were subjected to partial 16S  
99 rRNA gene sequencing using the primers and PCR conditions as described previously.  
100 [7] Amplified PCR products were sequenced by Sangon Biotech (Shanghai, China).  
101 Sequence similarity searches were carried out using BLAST tool (NCBI:  
102 <https://www.ncbi.nlm.nih.gov/>) [8].

### 103 **Antimicrobial susceptibility testing**

104 A panel of 9 antibiotics were selected to determine the antimicrobial susceptibility of  
105 all *S. aureus* isolates, including ceftazidime (FOX/30 µg), chloramphenicol (C/30 µg),  
106 clindamycin (DA/2 µg), erythromycin (E/15 µg), gentamicin (CN/10 µg), penicillin  
107 (PG/10 unit), rifampin (RD/5 µg), teicoplanin (TEC/30 µg), and tetracycline (T/30 µg).  
108 In addition, the minimum inhibitory concentrations (MICs) for ceftazidime were  
109 determined using E-test (Biomérieux, Basingtoke, UK) The results were interpreted  
110 as susceptible, intermediate resistant, or resistant according to the recommendations of  
111 Clinical and Laboratory Standards Institute (CLSI: 24th edition) [9].

### 112 **Determination of *mecA* gene and SCC*mec* types**

113 Genomic DNA of all *S. aureus* isolates were prepared using commercial DNA  
114 extraction kit (Solarbio Co. Ltd, China) according to the manufacturer's instructions.  
115 *mecA* gene was determined using the PCR protocol and primers as described by Kondo  
116 et al [10]. SCC*mec* types were determined for all MRSA isolates using a combination  
117 of *mec* and *ccr* gene complexes [10].

### 118 **Determination of *pvl*, *ica* and enterotoxin genes**

119 *pvl* gene was determined for all *S. aureus* as described previously [11]. Biofilm  
120 production was determined using *icaR* forward and reverse primers [12]. Seventeen  
121 enterotoxin genes (*sea*, *seb*, *sec*, *sed*, *see*, *seg*, *seh*, *sei*, *sej*, *sek*, *sel*, *sem*, *sen*, *seo*, *sep*,  
122 *ser*, *seu*) and the *tsst* gene were detected for 59 *S. aureus* by using a protocol as  
123 described previously [13].

### 124 **Multi-locus sequence typing**

125 Multilocus sequence typing (MLST) was used to determine the sequence types of all *S.*  
126 *aureus* isolates (<https://pubmlst.org/saureus/info/primers.shtml>). The amplicons were  
127 sequenced by Sangon biotech (Shanghai, China). The sequence types were assigned by  
128 comparing the combination of seven alleles to those in the *S. aureus* database  
129 (<https://pubmlst.org/saureus/>).

### 130 ***spa* typing**

131 The x- region of the protein A (*spa*) gene of all *S. aureus* isolates was amplified using  
132 *spa* F (5'- AGACGATCCTTCGGTGAGC-3') and *spa* R (5'-GCTTTTGCAATG  
133 TCATTTACTG-3') primers. Amplified PCR products were sequenced by Sangon  
134 Biotech (Shanghai, China). The *spa* types were then determined using the BioNumerics  
135 software *spa* typing tool ( Applied Maths, Belgium) [14].

### 136 **Statistical analysis**

137 The  $\chi^2$  test was used to analyze the quantitative variables. A *P*-value < 0.05 was  
138 considered statistically significant.

## 139 **Results**

### 140 ***S. aureus* isolates**

141 Over the 22 months period between 2017-2019, 535 gram-positive isolates were  
142 recovered from a total of 368 samples taken from 276 hospital personnel in four tertiary  
143 hospitals, including 196 isolates recovered from 108 hospital personnel in hospital I  
144 (H-I); 101 isolates recovered from 43 hospital personnel in hospital II (H-II), 174  
145 isolates recovered from 100 hospital personnel in hospital III (H-III) and 64 isolates  
146 were recovered from 25 hospital personnel in hospital IV (H-IV). Fifty-nine (11%)

147 isolates were identified as *S. aureus*, 338 isolates were determined to be coagulase  
148 negative staphylococci, and 138 isolates were identified as non-staphylococcal isolates,  
149 including those from *Bacillus*, *Micrococcus*, and *Enterococcus* genus. 34 *S. aureus*  
150 were recovered from hospital personnel in H-II, 21 from hospital personnel in H- I, 2  
151 from hospital personnel in H-III and 2 from hospital personnel in H- IV (Table 1).  
152 Thirty-one out of 276 (11%) hospital personnel carried *S. aureus*, whereas eleven out  
153 of 276 (4%) were MRSA carriers. MRSA carriers were from five departments of 4  
154 tertiary hospitals, including Gastroenterology department (GD), Emergency unit (ER),  
155 Medical Examination Center (MEC), Obstetrics and Gynecology department (OG) and  
156 Hepatobiliary Surgery department (HPS). Hospital personnel who carried *S. aureus*  
157 were from eight departments of 4 tertiary hospitals, including Gastroenterology  
158 department (GD), Dermatology department (DT), Emergency unit (ER), Hepatobiliary  
159 Surgery department (HPS), Medical Examination Center (MEC), Obstetrics and  
160 Gynecology department (OG), Thoracic Surgical department (TS), and Ultrasonic room  
161 (UR). No *S. aureus* was recovered from personnel in the Endocrine, Rehabilitation,  
162 Chinese medicine, Urology, Oncology departments and Clinical laboratory.

### 163 **Antimicrobial susceptibility test**

164 Forty-five (76%) *S. aureus* were resistant to penicillin, followed by 24 (41%) *S. aureus*  
165 were resistant to erythromycin, 20 (34%) to clindamycin, 14 (24%) to cefoxitin, 7 (12%)  
166 to teicoplanin, 3 (5%) to tetracycline, 3 (5%) to gentamicin, 2 (3%) to chloramphenicol,  
167 and 1(2%) to rifampicin. In addition, 26 (44%) *S. aureus* showed intermediate  
168 resistance towards erythromycin, and only 9 (15%) isolates were fully susceptible to

169 erythromycin (Tables S1). Fifty-one (86%) isolates were resistant to at least 2  
170 antibiotics. MICs to ceftazidime varied ranging from 1.5 to 8 µg/ml (Table 1).

#### 171 ***mecA* gene and *SCCmec* typing results of *S. aureus***

172 *mecA* gene was determined for all *S. aureus* isolates (n=59), of which 14 (24%) were  
173 *mecA* positive. *SCCmec* types were determined in 14 *mecA* positive *S. aureus*. Five  
174 isolates harbored *SCCmec* type IV, 3 isolates carried *SCCmec* type V and 1 isolate  
175 *SCCmec* type II. We were not able to assign *SCCmec* types to four of the isolates due  
176 to the lack of *mec* complex. In these isolates we were only able to identify type 2 *ccr*  
177 complex. In addition, we were not able to identify either *mec* and *ccr* gene complexes  
178 in one *S. aureus* isolate (Table 1).

#### 179 **Determination of *pvl*, *ica*, *tsst* and enterotoxin genes**

180 *pvl*, *ica*, *tsst* and enterotoxin genes were determined for 59 *S. aureus* isolates. 7 (12%)  
181 out of 59 isolates were *pvl* gene positive, including 3 MRSA and 4 MSSA. Of 59 isolates,  
182 the *ica* gene was detected in 5 (8%) isolates, including 2 MRSA and 3 MSSA. The toxic  
183 shock syndrome toxin gene was detected in 2 (3.4%) MRSA isolates. In addition,  
184 determination of enterotoxin genes resulted to the following: *seg* (n=47, 80.0%), *sen*  
185 (n=33, 55.9%), *seb* (n=19, 32.2%), *sei*(n=14, 23.7%), *seo* (n=13, 22%), *sem* (n=12,  
186 20.3%), *ser* (n=11, 18.6%), *see* (n=7, 11.9%), *sea* (n=3, 5.1%),*sed* (n=2, 3.4%), *seu*  
187 (n=2, 3.4%), *seh* (n=1,1.7%).*sel* (n=1, 1.7%), *sek* (n=1, 1.7%), *seq* (n=1, 1.7%), *sec*  
188 (n=0) and *sej*(n=0) (Table 2).

#### 189 **MLST typing**

190 Multi-locus sequence types were determined for 49 *S. aureus* isolates, including ST5

191 (n=5), ST6 (n=3), ST7(n=3), ST15 (n=10), ST25 (n=5), ST59 (n=2), ST88 (n=3),  
192 ST188 (n=2), ST398 (n=10), ST630 (n=5) and ST943 (n=1) (Table 1).

### 193 ***spa* typing results**

194 *spa* typing of *S. aureus* isolates revealed that the isolates possessed diverse *spa* types ,  
195 including t034 (n=12), t078 (n=6), t084 (n=6), t189 (n=2), t227(n=1), t289 (n=1), t346  
196 (n=2), t437 (n=2), t491 (n=2), t701 (n=3), t796 (n=3), t954 (n=2), t1794(n=1), t2196  
197 (n=4), t2279 (n=1), t8862 (n=3), t8945 (n=3), t11653(n=2) and t14014 (n=2) (Table  
198 1,S1) (Fig 1).

### 199 **Discussion**

200 *S. aureus* is a major nosocomial pathogen associated with mild to life-threatening  
201 infections. It has been evidenced that the carriage of *S. aureus* plays an important role  
202 in the pathogenesis of infections [1]. Hospital personnel play important role in  
203 transmission of healthcare associated pathogens [3]. In this study, we report the  
204 antibiotic susceptibility, molecular characterisation and genetic diversity of  
205 MRSA/MSSA recovered from four tertiary hospital personnel in Tianjin, China.

206 In this study, 31/276 (11%) hospital personnel carried *S. aureus*, and eleven (4%) were  
207 carriers of MRSA, which is consistent with the average MRSA carriage rates of  
208 healthcare workers [3].

209 Fourteen (24%) *S. aureus* isolates were resistant to ceftazidime, 45 (76%) isolates were  
210 resistant to penicillin, 24 (41%) isolates were resistant to erythromycin, 20 (34%)  
211 isolates were resistant to clindamycin, and only one isolate (2%) was resistant to  
212 rifampicin, which was lower than the rates reported for hospital-associated *S. aureus*

213 isolates by others [7, 15]. In addition, it is worth to note that 44% of *S. aureus* showed  
214 intermediate resistance to erythromycin, and only 9 (15%) isolates were fully  
215 susceptible to erythromycin. It has been reported that erythromycin was one of the most  
216 frequently prescribed antibiotics in China between 2004 to 2012[16]. However, recent  
217 reports suggest that its annual use continues to increase [16]. The misuse and over  
218 prescription of erythromycin may have contributed to the unusual high levels of  
219 erythromycin resistance and intermediate resistance in *S. aureus* that were recovered  
220 from hospital personnel in this study. Fifty-seven (97%) *S. aureus* were resistant to at  
221 least one antibiotic, and only two isolates (3%) were fully susceptible to all 9 antibiotics  
222 tested.

223 SCCmec type I, II and III were reported to be hospital associated, whereas SCCmec  
224 types IV and V have been associated with the community [17]. In this study, the  
225 majority (n=8) of *S. aureus* carried community associated SCCmec elements, and one  
226 *S. aureus* harboured type II SCCmec. Four *S. aureus* carried SCC due to harbouring *ccr*  
227 but lacked the *mec* gene complex. In addition, one *S. aureus* was identified to carry  
228 Pseudo ( $\psi$ ) SCC due to lack of both the *mec* gene complex and *ccr* gene complex [18].  
229 Our data demonstrate the complex diversity of SCCmec and SCC elements in *S. aureus*  
230 isolates recovered from hospital personnel.

231 The prevalence of SE genes in clinical *S. aureus* was reported to descent in the  
232 following order: *ser*>*sek*>*sem*>*sei*>*sen*>*seg*>*seu*>*sej*>*sed*>*seo*>*sec*>*sel*>*seq*> *seb*>*tsst*>  
233 *sea*>*seh*>*see* [13]. In contrast, in this study *seg* (80.0%), *sen* (55.9%) and *seb* (32.2%)  
234 genes were the most prevalent SE genes in *S. aureus* isolates recovered from hospital

235 personnel. Contrary to previous studies that detected no *see* gene in clinical *S. aureus*  
236 isolates [13], the *see* gene was detected in 7 isolates in this study (Table 2). The  
237 abundance of SEs in *S. aureus* that were recovered from hospital personnel in this study  
238 is rather worrying finding.

239 Tianjin is one of the 12 major cities in China that was included in previous China  
240 National surveillance studies (CNSS) of clinical *S. aureus* in 2013 [4, 19]. Here, we  
241 carried out a pilot study to provide details of *S. aureus* carriage among the hospital  
242 personnel in four tertiary hospitals in Tianjin, China. The CNSS reported that MRSA  
243 ST239-t030/t037-SCC*mec*III and ST5-t002/t570-SCC*mec*II were the predominant  
244 genotypes causing infections in China [4, 19]. Moreover, the ST239-t030 was also  
245 reported to be the dominant clinical MRSA clone in Tianjin [12]. In this study, no  
246 MRSA ST239-t030 and ST5-t002/t570 genotypes were recovered from hospital  
247 personnel. The dominant genotype of MRSA that were recovered from hospital  
248 personnel in this study included ST398-t034-SCC*mec*IV/V, and ST630-t084/t2196,  
249 which was not consistent with the major MRSA genotypes reported by the CNSS [4,  
250 19].

251 In China, MRSA ST398 accounts for nearly 20% of skin and soft-tissue infections [20].  
252 MRSA ST398-t034-SCC*mec*IV/V was one of the predominant genotypes among  
253 hospital personnel in this study, thus posing a risk both to patients and the hospital  
254 personnel. Furthermore, it has previously been reported that *pvl* positive MRSA ST398-  
255 t034 was a cause of human infections in Sweden [21] and China [20]. In this study, two  
256 out of 10 (17%) *S. aureus* ST398-t034 recovered from hospital personnel harboured the

257 *pvl* gene, including one MRSA and one MSSA ST398-t034 isolates respectively.

258 In this study, no MRSA ST239 was recovered from hospital personnel, however, we  
259 identified four MRSA ST630-t2196/t084. ST630 and ST239 belong to clonal complex  
260 (CC) 8 [4], however, ST630 is a variant of ST239 clone and possesses changes  
261 within the *arcC* and *aroE* locuses [22]. To this end, MRSA ST630-t4549 was reported  
262 to cause endocarditis and bacteremia [20,21]. Moreover, *pvl* positive MRSA ST59-t437  
263 found in our study is a well-known community associated MRSA that was first reported  
264 in the USA in 2005 [23], but has since emerged worldwide as a life-threatening  
265 pathogen [24].

266 He et al., reported that ST7-t091/t796, ST188-t189 and ST398-t571/t034 were the main  
267 genotypes of MSSA that cause bacteremia in China, followed by ST15-t084 [4]. In this  
268 study, 45 (76%) MSSA isolated from hospital personnel belonged to two major  
269 genotypes: ST15-t078/t084/t346/t796/t8862/t8945/t11653 (n=9), and ST398-  
270 t189/t034/t078/t084/t14014 (n=6). Our findings were consistent with data reported for  
271 MSSA (ST398-t034 and ST15-t084) that have previously been isolated from clinical  
272 specimens [12]. Three MSSA ST88-t034/t14014 were recovered in this study. MSSA  
273 ST88 was reported to be the most common clone that causes soft-tissue and blood  
274 infections [20], and thus the prevalence of MSSA ST88 among hospital personnel in  
275 this study may pose a potential risk for patients to acquiring *S. aureus* infections while  
276 in the hospital.

277 This study has a number of limitations: only samples recovered from the hospital  
278 personal were included. No samples from patients or community were included to

279 examine the cross-transmission.

280 To our knowledge, this is the first detailed molecular characterization of MRSA and  
281 MSSA recovered from hospital personnel in Tianjin, China. Whether our findings do  
282 represent the issue in other parts of China remains to be addressed. In our study, we did  
283 find that the predominant genotype of MRSA recovered from hospital personnel in  
284 Tianjin was different from the main genotypes responsible for infections in China,  
285 whereas, the dominant genotype of MSSA isolated from hospital personnel was  
286 consistent with the main MSSA genotypes recovered from the clinic. Due to their  
287 previous association with hospital infections, the *S. aureus* clones identified in this  
288 study may well pose a health threat to patients, their family members as well as the  
289 hospital personnel. Therefore, it is necessary to adapt a regular National screening  
290 program for hospital personnel to better identify such clones and associated risks they  
291 pose.

## **Author statement**

### **Authors and contributors**

ZX: conceptualization, methodology, software, validation, resources, data curation, writing-original draft preparation visualization, supervision, project administration and funding. XDL, DT: formal analysis, investigation. ZYS, LQG, CXD: investigation. NJT: writing-review and editing, HVM: conceptualization, methodology, writing-review and editing. All authors read and approved the final manuscript.

### **Conflicts of interest**

The authors declare that there are no conflicts of interest

### **Funding information**

This work was supported by the Tianjin Municipal Science and Technology Commission [17JCYBJC43000]

### **Ethical approval**

The research protocol and informed consent was approved by the Ethics committee of Tianjin science and technology commission (approval No TMUaMEC2017017).

### **Consent for publication**

No applicable

### **Acknowledgement**

No applicable

## References:

1. **Von EC, Becker K, Machka K, Stammer H, Peters G.** Nasal carriage as a source of *Staphylococcus aureus* bacteremia. Study Group. *N Engl J Med* 2001;344:11–16.
2. **Haddadin AS, Fappiano SA, Lipsett PA.** Methicillin resistant *Staphylococcus aureus* (MRSA) in the intensive care unit. *Postgrad Med J* 2002;78:385–392.
3. **Albrich WC, Harbarth S.** Health-care workers: source, vector, or victim of MRSA? *Lancet Infect Dis* 2008;8:289–301.
4. **He W, Chen H, Zhao C, Zhang F, Li H, et al.** Population structure and characterisation of *Staphylococcus aureus* from bacteraemia at multiple hospitals in China: association between antimicrobial resistance, toxin genes and genotypes. *Int J Antimicrob Agents* 2013;42:211–219.
5. **Gushiken CY, Medeiros LB, Correia BP, Souza JM, Moris DV, et al.** Nasal carriage of resistant *Staphylococcus aureus* in a medical student community . *Anais da Academia Brasileira de Ciências* 2016;88:1501–1509.
6. **Zapka C, Leff J, Henley J, Tittl J, De Nardo E, et al.** Comparison of Standard Culture-Based Method to Culture-Independent Method for Evaluation of Hygiene Effects on the Hand Microbiome. *MBio* 2017;8:e00093-17.
7. **Xu Z, Mkrtchyan H V, Cutler RR.** Antibiotic resistance and *mecA* characterization of coagulase-negative staphylococci isolated from three hotels in London, UK. *Front Microbiol* 2015;6:947.
8. **Mkrtchyan H V., Russell CA, Wang N, Cutler RR.** Could Public Restrooms

- Be an Environment for Bacterial Resistomes? *PLoS One* 2013;8:e54223.
9. **Wayne PA.** *CLSI Performance standard of Antimicrobial Susceptibility Testing: Twenty-fourth International Supplement.* 2014.
  10. **Kondo Y, Ito T, Ma XX, Watanabe S, Kreiswirth BN, et al.** Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: rapid identification system for mec, ccr, and major differences in junkyard regions. *Antimicrob Agents Chemother* 2007;51:264–74.
  11. **Goryachev BE, Nikolaev AA.** Development of a triplex real-time PCR assay for detection of Panton-Valentine leukocidin toxin genes in clinical isolates of methicillin-resistant *Staphylococcus aureus*. *J Clin Microbiol* 2005;43:6147–6149.
  12. **Cafiso V, Bertuccio T, Santagati M, Campanile F, Amicosante G, et al.** Presence of the ica operon in clinical isolates of *Staphylococcus epidermidis* and its role in biofilm production. *Clin Microbiol Infect* 2010;10:1081–1088.
  13. **Varshney AK, Mediavilla JR, Robiou N, Guh A, Wang X, et al.** Diverse enterotoxin gene profiles among clonal complexes of *Staphylococcus aureus* isolates from the Bronx, New York. *Appl Environ Microbiol* 2009;75:6839–6849.
  14. **Shah HN, Gharbia SE, Zhen X, Olkun A, Vranckx K, et al.** *Subtyping of Staphylococcus spp. Based upon MALDI-TOF MS Data Analysis.* 2017.
  15. **Wu T-H, Lee C-Y, Yang H-J, Fang Y-P, Chang Y-F, et al.** Prevalence and molecular characteristics of methicillin-resistant *Staphylococcus aureus* among

- nasal carriage strains isolated from emergency department patients and healthcare workers in central Taiwan. *J Microbiol Immunol Infect* 2019;52:248–254.
16. **Niu J.** Analysis on current situation and development trend of erythromycin API market. *China Mark* 2014;10:109–110.
  17. **Oliveira DC, Tomasz ALH.** Secrets of success of a human pathogen: molecular evolution of pandemic clones of methicillin-resistant *Staphylococcus aureus*. *Lancet Infect Dis* 2002;2:180–189.
  18. **Shore AC, Coleman DC.** Staphylococcal cassette chromosome mec: Recent advances and new insights. *Int J Med Microbiol* 2013;303:350–359.
  19. **Xiao M, Wang H, Zhao Y, Mao LL, Brown M, et al.** National surveillance of methicillin-resistant *Staphylococcus aureus* in China highlights a still-evolving epidemiology with 15 novel emerging multilocus sequence types. *J Clin Microbiol* 2013;51:3638–3644.
  20. **Yu F, Chen Z, Liu C, Zhang X, Lin X, et al.** Prevalence of *Staphylococcus aureus* carrying Panton-Valentine leukocidin genes among isolates from hospitalised patients in China. *Clin Microbiol Infect* 2008;14:381–384.
  21. **Al WOE.** Infection with Panton-Valentine Leukocidin–Positive Methicillin-Resistant *Staphylococcus aureus* t034. *Oxford Med Case Reports* 2015;2015:364–366.
  22. **Peck KR, Baek JY, Song J-H, Ko KS.** Comparison of Genotypes and Enterotoxin Genes Between *Staphylococcus aureus* Isolates from Blood and

- Nasal Colonizers in a Korean Hospital. *J Korean Med Sci* 2009;24:585–591.
23. **Pan ES, Diep BA, Charlebois ED, Auerswald C, Carleton HA, et al.**  
Population Dynamics of Nasal Strains of Methicillin-Resistant *Staphylococcus aureus*—and Their Relation to Community-Associated Disease Activity. *J Infect Dis* 2005;192:811–818.
24. **Sawanobori E, Hung WC, Takano T, Hachuda K, Horiuchi T, et al.**  
Emergence of Panton-Valentine leukocidin-positive ST59 methicillin-susceptible *Staphylococcus aureus* with high cytolytic peptide expression in association with community-acquired pediatric osteomyelitis complicated by pulmonary embolism. *J Microbiol Immunol Infect* 2015;48:565–573.

Table 1 Molecular characterization and antimicrobial susceptibility of methicillin-resistant *Staphylococcus aureus* (MRSA) recovered from four tertiary hospitals in Tianjin, North China

No	Hospital	Sources	Personnel ID	Sites	CC	ST	<i>spa</i> types	SCC <i>mec</i> types	<i>mecA</i>	MIC (FOX) $\mu$ g/ml	Antibiotic resistance pattern
<b>1</b>	A	ER	525	H	CC15	15	t084	V	+	<b>8</b>	FOX-PG-E(I)
<b>2</b>	A	ER	515	N	CC25	25	t227	Pseudo ( $\psi$ ) SCC	+	<b>2</b>	FOX-PG-CN-TEC
<b>3</b>	A	OG	3	H	CC59	59	t437	II	+	<b>2</b>	FOX-PG-E-TEC-DA
<b>4</b>	A	HPS	21	H		59	t437	IV	+	<b>6</b>	FOX-PG-E-T-DA
<b>5</b>	B	HPS	23	N	CC398	398	t034	IV	+	<b>2</b>	FOX-PG-E-DA
<b>6</b>	B	HPS	10	N		398	t034	IV	+	<b>8</b>	FOX-E-DA
<b>7</b>	B	HPS	23	N		398	t034	V	+	<b>1.5</b>	FOX-PG-E-DA
<b>8</b>	C	OG	74	H		398	t034	V	+	<b>3</b>	FOX

<b>9</b>	C	OG	43	H		UT	t034	IV	+	<b>6</b>	FOX-PG-E
<b>10</b>	D	MEC	22	N	CC8	630	t084	IV	+	<b>6</b>	FOX-E-T-DA
<b>11</b>	B	HPS	1	H		630	t2196	SCC	+	<b>8</b>	FOX-PG-TEC-RD-E(I)
<b>12</b>	B	HPS	1	H		630	t2196	SCC	+	<b>3</b>	FOX-PG-TEC-E(I)
<b>13</b>	B	HPS	1	H		630	t2196	SCC	+	<b>3</b>	FOX-PG-TEC-E(I)
<b>14</b>	A	GD	405	N	CC7	943	t289	SCC	+	<b>3</b>	FOX-PG-T-TEC-E(I)

A: hospital 1; B: hospital 2; C: hospital 3; D: hospital 4; UT: un-typable, I: intermediate resistance, H: hands, N: anterior nares

DT: Dermatology department, ER: Emergency room, GD: gastroenterology department, HPS: Hepatobiliary Surgery department, MEC: Medical examination center, OG: Obstetrics and gynecology department, TS: Thoracic surgical department, UR: Ultrasonic room.

C: chloramphenicol (30 µg), CN: gentamicin, (10 µg), DA: clindamycin (2 µg), E: erythromycin (15 µg), FOX: cefoxitin (30 µg), PG: penicillin (10 unit), RD: rifampin, (5 µg), T: tetracycline (30 µg), TEC: teicoplanin (30 µg)

Table 2 Detection of the staphylococcal enterotoxin genes in *S. aureus* isolates recovered from hospital personnel in four tertiary hospitals in Tianjin, North China

SE gene	No of positive isolates			$\chi^2$	<i>P</i>
	Total (n=59)	MRSA (n=14)	MSSA (n=45)		
Classic SE genes	<i>sea</i>	0 (0)	3 (6.7)	0.98	>0.05
	<i>seb</i>	6 (42.9)	13 (28.9)	0.95	>0.05
	<i>sec</i>	0 (0)	0 (0)	-	-
	<i>sed</i>	0 (0)	2 (4.4)	0.64	>0.05
	<i>see</i>	1 (7.1)	6 (13.3)	0.39	>0.05
Non-classic SE genes:	<i>seg</i>	8 (57.1)	39 (86.7)	5.74	<b>&lt;0.05</b>
	<i>seh</i>	1 (7.1)	0 (0)	3.27	>0.05
	<i>sei</i>	6 (42.9)	8 (17.8)	3.71	>0.05
	<i>sej</i>	0 (0)	0 (0)	-	-
	<i>sek</i>	1 (7.1)	0 (0)	3.26	>0.05
	<i>sel</i>	0 (0)	1 (2.2)	0.32	>0.05
	<i>sem</i>	0 (0)	12 (26.7)	6	<b>&lt;0.05</b>
	<i>sen</i>	6 (42.9)	27 (60)	1.27	>0.05
	<i>seo</i>	1 (7.1)	12 (26.7)	2.36	>0.05
	<i>seq</i>	1 (7.1)	0 (0)	2.49	>0.05
	<i>ser</i>	1 (7.1)	10 (22.2)	1.6	>0.05

---

	<i>seu</i>	2 (14.3)	0 (0)	6.65	<b>&lt;0.05</b>
Other toxic factors	<i>tsst</i>	2 (14.3)	0 (0)	6.65	<b>&lt;0.05</b>
	<i>pvl</i>	3 (21.4)	4 (8.9)	1.6	>0.05
	<i>ica</i>	2 (14.3)	3 (6.7)	0.8	>0.05

---

Figure 1 Minimum spanning tree based on *spa* types of *S. aureus*

Each colour indicates an individual *spa* type; each circle represents one *spa* type. The pieces of section in each circle indicate the number of isolates.